Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
about
Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometryUltrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spotsA chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancyAtazanavir pharmacokinetics with and without tenofovir during pregnancyUsing Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adultsOnce vs. twice-daily lopinavir/ritonavir in HIV-1-infected children.Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai AdultsPhysiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancyLopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patientsReduced indinavir exposure during pregnancy.Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.State-of-the-art dried blood spot analysis: an overview of recent advances and future trends.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissuesTreatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe.Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.Thermal stability and hydration behavior of ritonavir sulfate: A vibrational spectroscopic approach.Voltammetric Behavior of Indinavir and Determination in Pharmaceutical Dosage Forms
P2860
Q28474772-431E187C-48EE-421F-A3F0-B4DF32D56EDAQ33633139-D9837D0E-CC97-4AAC-92A3-6C4A1961E71EQ34308783-78032EFB-768F-4AE4-857A-74F9AFE1AA66Q34677780-8F9A1FFF-4DF1-4312-83CA-D90136AC88F3Q34758192-BC16ADE4-7C9A-4403-87D6-77563EC8ABBFQ35074548-A9FE42E1-4A37-4718-970B-E09CF59CBBADQ35705368-3A4D42CD-52EB-41B4-B46A-A916B6348546Q35826532-39F6EC6E-B191-4E3C-BE39-51965548260AQ35947409-1B168F87-D82F-4E8D-B400-5B7D49D37AE7Q36094847-19C4EFE8-32E3-4495-BC58-E575350871FCQ36144257-028DFC1A-D721-486F-B5D1-E8FC8E3ED36CQ36282719-0C311C79-C24D-4031-A85F-8F65CE89AEF8Q36295441-4305025D-63A7-4090-A245-547521B85FFAQ36359372-DB685F18-4BA2-45BC-BC62-A563CCB3DE0EQ36599597-9739836A-A3F6-4526-A82C-9888A24E9E1EQ36683435-62CB23F6-A193-442F-A54D-4513E6FA8112Q36763067-AD45B22E-B775-4D45-90F1-C16B6795EE68Q37036468-C56B682E-4FD9-4340-8D62-0B68494C462DQ37161917-36DA603F-FDE8-4FC6-89DE-75F3E795E2F6Q37190708-830CA239-F7AB-4C33-BA57-86DEBD8C17CBQ37417511-5EDB945D-E7E2-46F6-9F37-66FBAA31692EQ38130332-27E2BB2B-D824-408A-849B-0DA7FA9FDE2EQ38954109-4C6AB785-8564-4A12-9615-416123BB331CQ39191315-782CCEEE-4413-49A8-93E1-20A26B6C8277Q40474323-60AC6F2C-49C1-4A1F-90FC-7550ACA734ABQ41696931-BA6A2FE1-0AAB-4A46-84C0-6C51B0C03FD6Q42758383-4F102FE0-BA13-487F-A464-32FC33494DA3Q42844098-474117B2-0B4A-40A4-9A78-3E0FCAB88EC1Q42938439-B373A329-AC05-4EF2-B4F2-B3DBE03D194DQ46558204-6DD20E66-15FD-455E-BA87-83F535BFF655Q48164420-D387FF12-D7D1-4514-9BA6-AFD1AF708206Q48504525-DFA970BC-0B9D-4338-B91E-E64B592FEB13Q58143938-FBCD625C-738F-4E95-876D-B1CBB2622EDF
P2860
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Simultaneous determination of ...... ormance liquid chromatography.
@en
Simultaneous determination of ...... ormance liquid chromatography.
@nl
type
label
Simultaneous determination of ...... ormance liquid chromatography.
@en
Simultaneous determination of ...... ormance liquid chromatography.
@nl
prefLabel
Simultaneous determination of ...... ormance liquid chromatography.
@en
Simultaneous determination of ...... ormance liquid chromatography.
@nl
P2093
P1476
Simultaneous determination of ...... ormance liquid chromatography.
@en
P2093
Verweij-Van Wissen CP
P304
P356
10.1097/00007691-200306000-00023
P577
2003-06-01T00:00:00Z